Linklaters has advised BNP Paribas, Deutsche Bank and J.P. Morgan on the bridge loan financing for Merck KGaA, supporting its proposed acquisition of Bio-Techne Corporation (NASDAQ: TECH) at a total enterprise value of approximately US$11.3bn.
The international cross-practice Linklaters team was led by Marc Trinkaus(Partner) and Urs Lewens (Counsel) (both Banking, Frankfurt).
Further team members were New York Partners Gregory Gewirtz (Corporate M&A), Philip Lee (Banking), Michelle Lo (Tax), Counsels Ulrich Johann (Tax, Frankfurt), Omer Harel (Tax), Senior Associates David Mba (Corporate M&A), Reuven Rosen (Tax, all NY), Managing Associate Alexandra Selezneva(Banking, Düsseldorf), as well as Associates Matthias Horváth (Banking) and Benedikt Kruse (Tax, both Frankfurt).
Linklaters is a market leader in syndicated lending, acquisition finance, and financing in the context of spinoff and other corporate reorganisations. The team have advised, amongst others, Continental on a €2.5bn syndicated credit facility for AUMOVIO in connection with the spin-off of the automotive segment as AUMOVIO group, E.ON SE in relation to a syndicated credit facility in the amount of €4.7bn and Bayer AG on a syndicated credit facility in the amount of €5bn.
